Furthermore, while the combination of docetaxel and carboplatin plus trastuzumab with or without pertuzumab have become the preferred regimen for neoadjuvant therapy in HER2‐positive breast cancer according to the 2022 NCCN guideline, at the time of design of this study in 2019, AC‐TH with or without pertuzumab were preferentially recommendations in NCCN guideline.14 This evidence concerns the gene ERBB2 and breast cancer.